Trulieve Cannabis (TRLV) Could Be 51% Undervalued After Georgia Medical Cannabis Expansion

Simply Wall St.07-02

Trulieve Cannabis (TRLV) stock is in focus after Georgia expanded its medical cannabis program under Senate Bill 220, allowing flower and vaporization products and broadening patient access across the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648957625?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-02 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648957625","market":"hk","top_or_hot":-1,"title":"Trulieve Cannabis (TRLV) Could Be 51% Undervalued After Georgia Medical Cannabis Expansion","media":"Simply Wall St.","content":"<div>\n<p>Trulieve Cannabis (TRLV) stock is in focus after Georgia expanded its medical cannabis program under Senate Bill 220, allowing flower and vaporization products and broadening patient access across the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/trulieve-cannabis-trlv-could-be-51-undervalued-after-georgia\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trulieve Cannabis (TRLV) Could Be 51% Undervalued After Georgia Medical Cannabis Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrulieve Cannabis (TRLV) Could Be 51% Undervalued After Georgia Medical Cannabis Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 11:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/trulieve-cannabis-trlv-could-be-51-undervalued-after-georgia><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Trulieve Cannabis (TRLV) stock is in focus after Georgia expanded its medical cannabis program under Senate Bill 220, allowing flower and vaporization products and broadening patient access across the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/trulieve-cannabis-trlv-could-be-51-undervalued-after-georgia\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNBS","symbol_name":"Amplify Seymour Cannabis ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/trulieve-cannabis-trlv-could-be-51-undervalued-after-georgia","article_id":"2648957625","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-trlv/trulieve-cannabis/news/trulieve-cannabis-trlv-could-be-51-undervalued-after-georgia","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648957625","pubTimestamp":1782964270,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Trulieve Cannabis (TRLV) stock is in focus after Georgia expanded its medical cannabis program under Senate Bill 220, allowing flower and vaporization products and broadening patient access across the state.\nSee our latest analysis for Trulieve Cannabis.\nTrulieve Cannabis shares have been volatile around the Georgia news. The latest share price is $9.54 after a 1 day share price return that declined 2.95%. However, a 90 day share price return of 57.95% and a 1 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNBS":"Amplify Seymour Cannabis ETF","MSOX":"AdvisorShares MSOX 2X Daily ETF","MJ":"Amplify Alternative Harvest ETF","MSOS":"AdvisorShares Pure US Cannabis ETF","BK4007":"制药","TOKE":"Cambria Cannabis ETF","YOLO":"AdvisorShares Pure Cannabis ETF","TRLV":"Trulieve Cannabis Corporation","WEED":"Roundhill Cannabis ETF"},"translate_title":"佐治亚州医用大麻扩张后，Trulieve Cannabis(TRLV)的价值可能被低估51%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MJ":1.5,"WEED":1.5,"TRLV":1.5,"YOLO":1.5,"CNBS":1.5,"MSOX":1.5,"MSOS":1.5,"TOKE":1.5},"content_text":"Trulieve Cannabis (TRLV) stock is in focus after Georgia expanded its medical cannabis program under Senate Bill 220, allowing flower and vaporization products and broadening patient access across the state. See our latest analysis for Trulieve Cannabis. Trulieve Cannabis shares have been volatile around the Georgia news. The latest share price is $9.54 after a 1 day share price return that declined 2.95%. However, a 90 day share price return of 57.95% and a 1 year total shareholder return of 148.44% indicate that momentum has been strong despite a 5 year total shareholder return that declined 74.83%. If you are looking beyond cannabis for other high growth stories, this could be a useful moment to check out 20 top founder-led companies With Trulieve Cannabis trading at $9.54 alongside a large gap to analyst targets and an indicated intrinsic discount, the key question is whether the stock still trades below its fundamentals or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 50.9% Undervalued The most followed narrative currently places Trulieve Cannabis fair value at $19.42 compared to the last close at $9.54, framing the stock as heavily discounted and tying that view to detailed assumptions about earnings power and margins.  A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.  Read the complete narrative. Want to see how Trulieve Cannabis gets from current losses to that earnings profile? The narrative leans on sharper margins, leaner revenue expectations and a future earnings multiple that undercuts today’s sector average. Result: Fair Value of $19.42 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Trulieve Cannabis narrative still hinges on regulatory outcomes and new investments paying off, so any tax setback or weak demand could quickly challenge it. Find out about the key risks to this Trulieve Cannabis narrative. Next Steps Given the mixed tone around Trulieve Cannabis, this is a good moment to move quickly, look through the underlying numbers and risks yourself, and then balance that against the potential rewards highlighted in 4 key rewards and 1 important warning sign Looking for more investment ideas beyond Trulieve Cannabis? If Trulieve Cannabis has your attention, do not stop there. Use this moment to scan other opportunities and keep your watchlist working hard for you.  Spot potential bargains early by checking stocks that appear mispriced using the 41 high quality undervalued stocks. Strengthen your portfolio's foundation by reviewing companies screened for resilient finances with the solid balance sheet and fundamentals stocks screener (47 results). Get ahead of the crowd by hunting for less followed opportunities through the screener containing 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Trulieve Cannabis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648957625","isCrawlerRequest":true}